Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vyome HoldingsHIND -0.50%11 Days Payable is 3,589.17 as of Mar. 2026, which is 94% above its 10-year median of 1,845.83. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 701 Biotechnology companies, Vyome Holdings ranks better than 93.3% on this metric.
The historical rank and industry rank for Vyome Holdings's Days Payable or its related term are showing as below:
HIND'
s Days Payable Range Over the Past 10 Years
Min: 902.49 Med: 1845.83 Max: 4271.01
Current: 4271.01
During the past 4 years, Vyome Holdings's highest Days Payable was 4271.01. The lowest was 902.49. And the median was 1845.83.
HIND's Days Payable is ranked better than 93.3% of 701
companies
in the Biotechnology industry
Industry Median: 113.36
vs HIND: 4271.01
Vyome Holdings's Days Payable
increased
from Mar. 2025 (1,017.94) to Mar. 2026 (3,589.17).
It may suggest that Vyome Holdingsdelayed paying its suppliers.
Vyome Holdings Days Payable Related Terms
Vyome Holdings Days Payable Historical Data
* Premium members only.
The historical data trend for Vyome Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vyome Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vyome Holdings Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vyome Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Vyome Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vyome Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vyome Holdings (HIND) has a Days Payable of 3,589.17 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vyome Holdings and its competitors. This is 94% above median its historical median of 1,845.83. Over the past decade, Vyome Holdings' Days Payable has ranged from 902.49 to 4,271.01. According to the industry distribution chart, Vyome Holdings ranks #47 out of 701 companies in the Biotechnology industry, placing it in the top 6.7%.
Is Vyome Holdings' Days Payable too high?
Vyome Holdings' current Days Payable of 3,589.17 is 94% above median its 10-year median of 1,845.83. Over the past 10 years, this metric has ranged from a low of 902.49 to a high of 4,271.01. The Biotechnology industry median Days Payable is 113.36. Vyome Holdings' value of 3,589.17 is 3066.2% above this industry median. Based on the distribution chart, Vyome Holdings ranks #47 out of 701 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' Days Payable compare to CTXR and MBRX?
According to the Biotechnology industry distribution chart, Vyome Holdings ranks #47 out of 701 companies for Days Payable. This places Vyome Holdings in the top 7% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.36. Vyome Holdings' value of 3,589.17 is 3066.2% above this benchmark. Historically, Vyome Holdings' own Days Payable has ranged from 902.49 to 4,271.01 over the past decade. While the company's 10-year median is 1,845.83 vs. the industry median of 113.36, Vyome Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vyome Holdings's current Days Payable of 3,589.17 is 3066.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vyome Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vyome Holdings's current Days Payable is 3,589.17, which is 94% above median its own 10-year median of 1,845.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current Days Payable of 3,589.17. The current Days Payable is 3,589.17, which is 94% above median its 10-year median of 1,845.83 and 3066.2% above the Biotechnology industry median of 113.36. Vyome Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vyome Holdings (HIND), the current Days Payable is 3,589.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score
Get the complete analysis for HIND
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIND has been successfully added to your 
